Format

Send to

Choose Destination
Curr Opin Pharmacol. 2007 Aug;7(4):412-7. Epub 2007 Jul 12.

Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.

Author information

1
The Kennedy Institute of Rheumatology Division, Imperial College London, 1 Aspenlea Road, London W6 8LH, UK. richard.o.williams@imperial.ac.uk

Abstract

The clinical success of TNFalpha blocking biologics in a growing number of immune-mediated pathologies, including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the importance of TNFalpha in driving chronic inflammation and represents an important step forward in the treatment of these conditions. TNFalpha blockade, however, is a treatment, rather than a cure, and is not effective in all patients or in all autoimmune diseases and further research is needed to get closer to a cure. Recently, the identification of a novel, IL-17 producing, T helper cell subset, that plays a dominant pathogenic role in animal models of autoimmunity, is a major advance on existing knowledge, although the role of these cells in human disease remains to be established. Cytokines driving angiogenesis are also important in disease chronicity and thus might be valid therapeutic targets.

PMID:
17627887
DOI:
10.1016/j.coph.2007.06.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center